# US 2024/0390404 A1 · Anti-human norovirus agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390404 A1
- Document ID: US20240390404A1
- Status: Published application
- Kind: A1
- Application number: 18/794,377
- Filed: 2024-08-05
- Published: 2024-11-28
- Earliest claimed: 2018-12-27
- Assignees: Keio University; The Kitasato Institute
- Applicants: Keio University; The Kitasato Institute
- Inventors: Kazuhiko KATAYAMA; Akira FUJIMOTO; Kei HAGA; Reiko TODAKA; Toshiro SATO
- Web page: https://patentgrep.com/patent/US20240390404A1

## CPC

- A61K 31/7024: Esters of saccharides
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: [In the formulas, each of formula (III) and formula (IV) represents an α-anomer or a β-anomer; each of R1, R3, and R4 is —OH or —OAc; R2 is a halogen atom, —OH, or —OAc; and R5 is —CH3, —C≡CH, —C≡CCH3, or —CH2C≡CH.]

## Claims

### Claim 1

A method of treating or preventing human norovirus infection, the method comprising administering, to a subject in need thereof, a fucose analog represented by formula (III):
wherein the formula (III) represents an α-anomer or a β-anomer; and
i) all of R1, R3, and R4 are —OAc, R2 is F (fluorine atom), and R5 is —CH3; or
ii) all of R1, R2, R3, and R4 are —OAc, and R5 is —C═CH, or a salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fucose analog or a salt thereof is administered to the subject at least once a day.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the fucose analog or a salt thereof is administered to the subject from 3 to 4 days before the subject is potentially infected with human norovirus.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fucose analog or a salt thereof is administered to the subject until human noroviral RNA disappears in feces of the subject.
